Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Events

05 Mar 2017 - 09 Mar 2017
20 Mar 2017 - 23 Mar 2017
12 Apr 2017 - 14 Apr 2017

Blocking Ether Lipid Synthesis Prevents Tumor Growth

By BiotechDaily International staff writers
Posted on 04 Sep 2013
ADVERTISEMENT
SARTORIUS AG
Tumor cells have elevated levels of ether lipids, and blocking the activity of an enzyme critical to their synthesis was found to have profound anticancer benefits.

Levels of ether lipids, which are lipids in which one or more of the carbon atoms on glycerol is bonded to an alkyl chain via an ether linkage as opposed to the usual ester linkage, are higher in tumors than in normal tissues, but their specific function in cancer has remained unclear.

In a recent study, investigators at the University of California, Berkeley (USA) looked at the metabolism of ether lipids and the ramifications of interfering with their synthesis.

They reported in the August 26, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that the metabolic enzyme alkylglyceronephosphate synthase (AGPS), which catalyzes a critical step in the synthesis of ether lipids, was upregulated across multiple types of aggressive human cancer cells and primary tumors. Inhibition of AGPS in cancer cells resulted in reduced cell survival, cancer aggressiveness, and tumor growth through altering the balance of ether lipid, fatty acid, eicosanoid, and fatty acid-derived glycerophospholipid metabolism, resulting in an overall reduction in the levels of several oncogenic signaling lipids.

"Cancer cells make and use a lot of fat and lipids, and that makes sense because cancer cells divide and proliferate at an accelerated rate, and to do that, they need lipids, which make up the membranes of the cell," said senior author Dr. Daniel Nomura, assistant professor of nutritional sciences and toxicology at the University of California, Berkeley. "The cancer cells were less able to move and invade. Lipids have a variety of uses for cellular structure, but what we are showing with our study is that lipids can also send signals that fuel cancer growth."

The investigators also evaluated the impact of inhibiting AGPS in mice that had been injected with cancer cells. "Among the mice that had the AGPS enzyme inactivated, the tumors were nonexistent," said Dr. Nomura. "The mice that did not have this enzyme disabled rapidly developed tumors."

Research is now underway to develop AGPS inhibitors for use in cancer therapy.

Related Links:
University of California, Berkeley




Channels

Drug Discovery

view channel
Image: The experimental drug NGI-1 slows cancer growth by blocking glycosylation of the epidermal growth factor receptor (EGFR), which is shown in the above diagram (Photo courtesy of Wikimedia Commons).

Experimental Drug Slows Lung Cancer Growth by Blocking Protein Glycosylation

An interesting new experimental anti-cancer drug slows growth of certain lung tumor cells by preventing the glycosylation of critical cell surface receptor proteins. Asparagine (N)-linked glycosylation... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Business

view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.